Etravirine for HIV-1-infected Patients Failing Antiretroviral Therapy

;em>REFERENCE: Lancet 2007; 370:39-48MARGARET JOHNSON, Royal Free Hospital, London
A new non-nucleoside reverse-transcriptase inhibitor has demonstrated its activity in patients infected with HIV-1. TMC125, or etravirine, was compared with placebo in over 500 treatment-experienced patients in the DUET-2 trial, and Derek Thorne heard more from Margaret Johnson of the Royal Free Hospital in London.